Abstract: FR-PO0810
Evaluation of Cardiovascular Risk Factors, Structure, and Function in an Interim Analysis of the SPARTAN Study: Sparsentan as First-Line Treatment of Incident Patients with IgAN
Session Information
- Glomerular Clinical Trials: From Data to Impact
November 07, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Cheung, Chee Kay, University Hospitals of Leicester NHS Trust, Leicester, England, United Kingdom
- Dhaun, Neeraj, Royal Infirmary of Edinburgh, Edinburgh, Scotland, United Kingdom
- Griffin, Sian V., University Hospital of Wales, Cardiff, Wales, United Kingdom
- Hendry, Bruce M., Travere Therapeutics Inc, San Diego, California, United States
- Howson, Alexandra Louise, University Hospitals of Leicester NHS Trust, Leicester, England, United Kingdom
- Komers, Radko, Travere Therapeutics Inc, San Diego, California, United States
- Mercer, Alex, JAMCO Pharma Consulting, Stockholm, Sweden
- Moody, Stephanie, Travere Therapeutics Inc, San Diego, California, United States
- Parke, Kelly, University Hospitals of Leicester NHS Trust, Leicester, England, United Kingdom
- Sayer, Matthew, Royal Infirmary of Edinburgh, Edinburgh, Scotland, United Kingdom
- Sinha, Smeeta, Northern Care Alliance NHS Foundation Trust, Salford, England, United Kingdom
- Willcocks, Lisa, Addenbrooke's Hospital, Cambridge, England, United Kingdom
- Barratt, Jonathan, University of Leicester, Leicester, England, United Kingdom
- Graham-Brown, Matthew, University of Leicester, Leicester, England, United Kingdom
Background
IgA nephropathy (IgAN) is associated with increased cardiovascular (CV) risk, due to factors including hypertension and myocardial remodelling. SPARTAN is an open-label, single-arm, exploratory trial, evaluating the safety and efficacy of sparsentan, a dual endothelin and angiotensin receptor antagonist (DEARA), as first-line therapy in adults with IgAN. We report findings from a pre-specified 24-week interim analysis, focusing on CV risk factors and cardiac magnetic resonance imaging (MRI) studies.
Methods
12 adults with biopsy-proven IgAN within 6 months, proteinuria ≥0.5 g/d, eGFR ≥30 mL/min/1.73 m2, and no prior ACEi/ARB treatment were enrolled. Sparsentan treatment is for 110 weeks. One patient discontinued early due to hypotension. Data from assessments through to Week 24, including cardiac MRI studies at baseline and Week 24, were analysed.
Results
At baseline, mean age was 35.8 y (SD 12.2), median proteinuria 1.7 g/d (IQR 0.6-3.3) and mean eGFR 70.2 ml/min/1.73m2 (SD 25.0). Treatment with sparsentan resulted in rapid and sustained reductions in proteinuria of ~70% over 24 wks. Blood pressure declined initially then remained stable (-15/-8 mmHg at Week 24). By Week 24, mean body weight reduced by 1.0 kg (SD 3.3), mean total body water measured by bioimpedance decreased by 4.4 L (SD 14.8), and NT-proBNP levels declined (mean change -11.2 ng/mL, SD 52.0).
Paired cardiac MRI studies in 8 participants demonstrated a reduction in left ventricular (LV) mass (mean change -3.1g/m2, SD 3.5) at Week 24, suggestive of early reverse remodelling. LV ejection fraction remained stable (+0.3%, SD 6.6), and LV stroke volume increased slightly (+2.1 mL, SD 5.6). Native T1 and T2 times increased modestly (+12.9 ms [SD 35.1] and +2.3 ms [SD 3.8], respectively). RV parameters were largely unchanged.
Conclusion
In newly diagnosed IgAN patients, sparsentan led to rapid proteinuria reductions and was associated with favourable trends in blood pressure, LV mass and CV biomarkers, with no evidence of fluid retention or myocardial compromise. These findings support the cardiovascular safety of sparsentan as a first-line therapy in IgAN.
Funding
- Commercial Support – Travere Therapeutics